Loading stock data…
TVTX
$44.12+2.00 (+4.75%)
Market ClosedLast close May 1
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Travere Therapeutics, Inc. in the Healthcare sector is trading at $44.12. The stock is currently near its 52-week high of $44.70, remaining 53.4% above its 200-day moving average. Technical signals show overbought RSI of 77 and bullish MACD crossover, explaining why TVTX maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 77) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$44.12
Potential Upside
5%
Whystock Fair Value$46.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$49.64+12.5%
Range$40.00 – $56.00
Fundamentals
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, o...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.70B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-147.23%
Volume
Today's trading volume
2.19M
Recent News
XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?
XOMA Royalty (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal
Ligand Pharmaceuticals snatched up Xoma Royalty in a deal worth $739 million, the companies said Monday as both biotech stocks jumped.
Travere Therapeutics Inc. (TVTX): First-Mover Advantage Is Massive Moat
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Travere Therapeutics, Inc. (NASDAQ:TVTX) ranks 7th on this list. Investor interest in Travere Therapeutics, Inc. (NASDAQ:TVTX) has spiked since a landmark regulatory win. Earlier this month, drug authorities granted full approval of FILSPARI for focal segmental glomerulosclerosis (FSGS). ILSPARI is […]
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?
Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.’s share was trading at $40.29 as of April 20th. TVTX’s forward P/E was 54.35 , respectively according to Yahoo Finance. Travere Therapeutics, Inc., a biopharmaceutical company, identifies, […]
Is It Time To Reassess Travere Therapeutics (TVTX) After Its Recent Price Surge
If you are wondering whether Travere Therapeutics at around US$38.78 is offering value or asking too much, this breakdown is designed to help you make sense of the current price. The stock has been volatile recently, with a 44.5% return over the last 30 days, a 144.2% return over 1 year, and a 1.9% decline year to date. Recent news flow around Travere Therapeutics has focused on its position in the biotech space and investor reactions to company specific updates, which helps explain some of...